Thymidylate synthase as a prognostic biomarker for locally advanced XXXX after multimodal treatment.

@entity1 @entity901 @entity1382 @entity5 @entity188 @entity348 @entity3 @entity1487
PURPOSE: For years, @entity1487 ( @entity1487 ) has been the backbone of radiochemotherapy (RCT) of locally advanced @entity5 . Its main target, @entity1382 ( @entity1382 ), is speculated to be an important biomarker for response prediction and long-term prognosis. In this study, we analyzed @entity1382 expression in the @entity5 tissue of 208 @entity1 to evaluate its predictive/prognostic potential. METHODS: All @entity1 included were diagnosed with locally advanced @entity188 (UICC II and III) and were treated within randomized clinical trials of the German @entity5 Study Group. Preoperative RCT (50.4  Gy and concomitant either @entity1487 or @entity1487 and @entity901 ) was administered in 167 @entity1 followed by surgical resection with @entity348 ( @entity348 ). Another 41 @entity1 received postoperative RCT. @entity1382 levels and further clinicopathological parameters were assessed in univariate and multivariate analyses. Additionally, a @entity1382 gene polymorphism was analyzed with respect to the intratumoral protein levels. RESULTS: Low @entity1382 expression in pretreatment biopsies correlated with impaired @entity1 survival (p  =  0.015). Analysis of a 28-bp repeat revealed a correlation between the *3/*3 genotype and high @entity1382 expression in pretherapeutic biopsies. In this study, a correlation of @entity1382 expression and grade of RCT-induced @entity5 regression was not found. Histopathological examination confirmed a complete @entity5 remission in 16 @entity1 (9.6%). Analyses of the resection specimen indicated an unfavorable prognosis for @entity1 with low intratumoral @entity1382 expression in case of detected lymph node @entity3 (p  =  0.04). CONCLUSIONS: @entity1382 can serve as a prognostic biomarker indicating an unfavorable prognosis for @entity1 with low @entity1382 expression.
